41 results on '"Brunelli, M"'
Search Results
2. 1476P Immunohistochemical (mIHC) analyses of the immune tumor microenvironment (I-TME) in metastatic renal cell carcinoma (mRCC) patients (pts) receiving immunotherapy: Main results from the Meet-URO 18 study
3. C9 - A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in 739 patients (pts) affected by early stage pure Invasive Lobular breast Carcinoma (ILC)
4. B5 - Addressing the best treatment for non-clear cell renal cell carcinoma (nccRCC): a meta-analysis of randomized clinical trials comparing VEGFR-TKis versus mTORi targeted therapies
5. A clinical–biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status
6. Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries
7. 802TiP Immune tumor microenvironment (TME) in correlation with peripheral blood immune biomarkers as prognostic factor in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: The multicentric retrospective Meet-URO 18 study
8. PROGNOSTIC VALUE OF VASCULAR AND LYMPHATIC INVASION IN PATIENTS WHO HAVE UNDERGONE RADICAL CYSTECTOMY FOR TRANSITIONAL CELL CARCINOMA OF THE BLADDER
9. Exploring resistance to nivolumab [NIV] applying an Immune Genomic Signature (IGS) in advanced pretreated NSCLC [PRINCiPe study]
10. Perihilar and distal extrahepatic cholangiocarcinomas show different genetic profiles but share MYC copy gain and TP53 mutation as independent poor prognostic markers
11. A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure invasive lobular breast carcinoma (ILC)
12. Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations
13. A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in 739 patients (pts) affected by early stage pure Invasive Lobular breast Carcinoma (ILC)
14. Results of an integrated multi-platforms analysis in squamous cell lung carcinoma (SqCLC) revealed PI3K/RICTOR-mTORC2 axis as a potential prognostic biomarker and druggable target
15. Addressing the best treatment for non-clear cell renal cell carcinoma (nccRCC): a meta-analysis of randomized clinical trials comparing VEGFR-TKis versus mTORi targeted therapies
16. PI3K/RICTOR-mTORC2 axis as a driver of prognosis and potential druggable target in squamous cell lung carcinoma (SqCLC)
17. ESR1, Ph-mTOR, CDK4/6 and PD-L1 expression as prognostic (and potentially druggable) drivers for pure invasive lobular breast carcinoma (ILC): Preliminary results of prognostic outliers according to a clinical-pathological model
18. 1584P - Exploring resistance to nivolumab [NIV] applying an Immune Genomic Signature (IGS) in advanced pretreated NSCLC [PRINCiPe study]
19. P-186 - Perihilar and distal extrahepatic cholangiocarcinomas show different genetic profiles but share MYC copy gain and TP53 mutation as independent poor prognostic markers
20. RICTOR/PI3K/mTOR as a clinically relevant driver of poor prognosis in squamous cell lung carcinoma (SqCLC): Preliminary results of prognostic outliers according to a validated clinicopathological model
21. Prognostic impact of proliferation for resected early stage breast cancer according to histology: Cut-off analysis of Ki67 in 859 patients with pure invasive lobular and ductal breast carcinoma (ILC/IDC)
22. Potentially druggable molecular and immune-related pathways drive the prognosis of resected squamous cell lung carcinoma (R-SqCLC): preliminary results of prognostic outliers according to a clinicopathological model
23. Prognostic impact of Ki67 for resected early stage pure Invasive Lobular breast Cancer (ILC): cut-off analysis and clinical validation
24. The incidence and relative risk of pulmonary toxicity (PT) in patients treated with anti-PD-1/PD-L1 targeted therapies for solid tumors
25. 1417P - Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations
26. 197P - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure invasive lobular breast carcinoma (ILC)
27. Autophagy and transplantation: organ injury and cancerogenesis by molecular expression of LC3B
28. Clinical and pathological predictors of Advanced Breast Carcinoma with Luminal subtype (ABC-Lum) identifying prognostic ‘outliers’: multicenter retrospective analysis in the ‘real-world’ scenario
29. De novo renal cell neoplasia after kidney transplantation, according to the International Society of Urological Pathology (ISUP 2013) Vancouver Classification
30. Development of a risk model to identity prognostic ‘outliers’ underwent surgery for early-stage invasive lobular breast carcinoma (ILBC) according to clinical and pathological factors
31. E10 - Results of an integrated multi-platforms analysis in squamous cell lung carcinoma (SqCLC) revealed PI3K/RICTOR-mTORC2 axis as a potential prognostic biomarker and druggable target
32. 1640P - PI3K/RICTOR-mTORC2 axis as a driver of prognosis and potential druggable target in squamous cell lung carcinoma (SqCLC)
33. 204P - ESR1, Ph-mTOR, CDK4/6 and PD-L1 expression as prognostic (and potentially druggable) drivers for pure invasive lobular breast carcinoma (ILC): Preliminary results of prognostic outliers according to a clinical-pathological model
34. Risk Stratification Model for Resected Squamous Cell Lung Cancer (R-Sqlc) Patients (Pts) According to Clinical and Pathological Factors
35. Loss of Chromosomes 9P and 14Q: Re-Profiling Metastatic Tissue for Re-Targeting Patients with Metastatic Renal Cell Carcinoma
36. 1182P - RICTOR/PI3K/mTOR as a clinically relevant driver of poor prognosis in squamous cell lung carcinoma (SqCLC): Preliminary results of prognostic outliers according to a validated clinicopathological model
37. M01 - The incidence and relative risk of pulmonary toxicity (PT) in patients treated with anti-PD-1/PD-L1 targeted therapies for solid tumors
38. F11 - Prognostic impact of Ki67 for resected early stage pure Invasive Lobular breast Cancer (ILC): cut-off analysis and clinical validation
39. A13 - Potentially druggable molecular and immune-related pathways drive the prognosis of resected squamous cell lung carcinoma (R-SqCLC): preliminary results of prognostic outliers according to a clinicopathological model
40. 1183PD - Risk Stratification Model for Resected Squamous Cell Lung Cancer (R-Sqlc) Patients (Pts) According to Clinical and Pathological Factors
41. 820P - Loss of Chromosomes 9P and 14Q: Re-Profiling Metastatic Tissue for Re-Targeting Patients with Metastatic Renal Cell Carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.